Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?

Cagno V, Tseligka ED, Jones ST, Tapparel C.

Viruses. 2019 Jul 1;11(7). pii: E596. doi: 10.3390/v11070596. Review.

2.

A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism.

Tseligka ED, Sobo K, Stoppini L, Cagno V, Abdul F, Piuz I, Meylan P, Huang S, Constant S, Tapparel C.

PLoS Pathog. 2018 Aug 3;14(8):e1007190. doi: 10.1371/journal.ppat.1007190. eCollection 2018 Aug.

3.

Antiviral drug screening by assessing epithelial functions and innate immune responses in human 3D airway epithelium model.

Boda B, Benaoudia S, Huang S, Bonfante R, Wiszniewski L, Tseligka ED, Tapparel C, Constant S.

Antiviral Res. 2018 Aug;156:72-79. doi: 10.1016/j.antiviral.2018.06.007. Epub 2018 Jun 8.

PMID:
29890184
4.

Biocompatible Zr-based nanoscale MOFs coated with modified poly(ε-caprolactone) as anticancer drug carriers.

Filippousi M, Turner S, Leus K, Siafaka PI, Tseligka ED, Vandichel M, Nanaki SG, Vizirianakis IS, Bikiaris DN, Van Der Voort P, Van Tendeloo G.

Int J Pharm. 2016 Jul 25;509(1-2):208-218. doi: 10.1016/j.ijpharm.2016.05.048. Epub 2016 May 26.

PMID:
27235556
5.

Development and Pharmacological Evaluation of New Bone-Targeted (99m)Tc-Radiolabeled Bisphosphonates.

Makris G, Tseligka ED, Pirmettis I, Papadopoulos MS, Vizirianakis IS, Papagiannopoulou D.

Mol Pharm. 2016 Jul 5;13(7):2301-17. doi: 10.1021/acs.molpharmaceut.6b00081. Epub 2016 May 31.

PMID:
27170456
6.

Pharmacological Development of Target-Specific Delocalized Lipophilic Cation-Functionalized Carboranes for Cancer Therapy.

Tseligka ED, Rova A, Amanatiadou EP, Calabrese G, Tsibouklis J, Fatouros DG, Vizirianakis IS.

Pharm Res. 2016 Aug;33(8):1945-58. doi: 10.1007/s11095-016-1930-4. Epub 2016 Apr 26.

PMID:
27115878

Supplemental Content

Loading ...
Support Center